207 related articles for article (PubMed ID: 34911567)
21. Cannabidiol and cannabis-inspired terpene blends have acute prosocial effects in the BTBR mouse model of autism spectrum disorder.
Staben J; Koch M; Reid K; Muckerheide J; Gilman L; McGuinness F; Kiesser S; Oswald IWH; Koby KA; Martin TJ; Kaplan JS
Front Neurosci; 2023; 17():1185737. PubMed ID: 37397463
[TBL] [Abstract][Full Text] [Related]
22. Cannabis-based medicines--GW pharmaceuticals: high CBD, high THC, medicinal cannabis--GW pharmaceuticals, THC:CBD.
Drugs R D; 2003; 4(5):306-9. PubMed ID: 12952500
[TBL] [Abstract][Full Text] [Related]
23. The therapeutic role of Cannabidiol in mental health: a systematic review.
Khan R; Naveed S; Mian N; Fida A; Raafey MA; Aedma KK
J Cannabis Res; 2020 Jan; 2(1):2. PubMed ID: 33526132
[TBL] [Abstract][Full Text] [Related]
24. A randomised controlled trial of vaporised Δ
Solowij N; Broyd S; Greenwood LM; van Hell H; Martelozzo D; Rueb K; Todd J; Liu Z; Galettis P; Martin J; Murray R; Jones A; Michie PT; Croft R
Eur Arch Psychiatry Clin Neurosci; 2019 Feb; 269(1):17-35. PubMed ID: 30661105
[TBL] [Abstract][Full Text] [Related]
25. Therapeutic Effects of Prolonged Cannabidiol Treatment on Psychological Symptoms and Cognitive Function in Regular Cannabis Users: A Pragmatic Open-Label Clinical Trial.
Solowij N; Broyd SJ; Beale C; Prick JA; Greenwood LM; van Hell H; Suo C; Galettis P; Pai N; Fu S; Croft RJ; Martin JH; Yücel M
Cannabis Cannabinoid Res; 2018; 3(1):21-34. PubMed ID: 29607408
[No Abstract] [Full Text] [Related]
26. CBD-enriched medical cannabis for intractable pediatric epilepsy: The current Israeli experience.
Tzadok M; Uliel-Siboni S; Linder I; Kramer U; Epstein O; Menascu S; Nissenkorn A; Yosef OB; Hyman E; Granot D; Dor M; Lerman-Sagie T; Ben-Zeev B
Seizure; 2016 Feb; 35():41-4. PubMed ID: 26800377
[TBL] [Abstract][Full Text] [Related]
27. Real world experience of patients with amyotrophic lateral sclerosis (ALS) in the treatment of spasticity using tetrahydrocannabinol:cannabidiol (THC:CBD).
Meyer T; Funke A; Münch C; Kettemann D; Maier A; Walter B; Thomas A; Spittel S
BMC Neurol; 2019 Sep; 19(1):222. PubMed ID: 31493784
[TBL] [Abstract][Full Text] [Related]
28. Oral medicinal cannabinoids to relieve symptom burden in the palliative care of patients with advanced cancer: a double-blind, placebo-controlled, randomised clinical trial of efficacy and safety of 1:1 delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD).
Hardy J; Haywood A; Gogna G; Martin J; Yates P; Greer R; Good P
Trials; 2020 Jul; 21(1):611. PubMed ID: 32631447
[TBL] [Abstract][Full Text] [Related]
29. Effect of Cannabidiol and Δ9-Tetrahydrocannabinol on Driving Performance: A Randomized Clinical Trial.
Arkell TR; Vinckenbosch F; Kevin RC; Theunissen EL; McGregor IS; Ramaekers JG
JAMA; 2020 Dec; 324(21):2177-2186. PubMed ID: 33258890
[TBL] [Abstract][Full Text] [Related]
30. Clinical and Preclinical Evidence for Functional Interactions of Cannabidiol and Δ
Boggs DL; Nguyen JD; Morgenson D; Taffe MA; Ranganathan M
Neuropsychopharmacology; 2018 Jan; 43(1):142-154. PubMed ID: 28875990
[TBL] [Abstract][Full Text] [Related]
31. Oral Cannabidiol Use in Children With Autism Spectrum Disorder to Treat Related Symptoms and Co-morbidities.
Barchel D; Stolar O; De-Haan T; Ziv-Baran T; Saban N; Fuchs DO; Koren G; Berkovitch M
Front Pharmacol; 2018; 9():1521. PubMed ID: 30687090
[No Abstract] [Full Text] [Related]
32. Cannabidiol-enriched medical cannabis as add-on therapy in children with treatment-resistant West syndrome: A study of eight patients.
Caraballo R; Valenzuela GR
Seizure; 2021 Nov; 92():238-243. PubMed ID: 34624613
[TBL] [Abstract][Full Text] [Related]
33. Cannabidiol for the treatment of autism spectrum disorder: hope or hype?
Pedrazzi JFC; Ferreira FR; Silva-Amaral D; Lima DA; Hallak JEC; Zuardi AW; Del-Bel EA; Guimarães FS; Costa KCM; Campos AC; Crippa ACS; Crippa JAS
Psychopharmacology (Berl); 2022 Sep; 239(9):2713-2734. PubMed ID: 35904579
[TBL] [Abstract][Full Text] [Related]
34. The Impact of Cannabidiol on Human Brain Function: A Systematic Review.
Batalla A; Bos J; Postma A; Bossong MG
Front Pharmacol; 2020; 11():618184. PubMed ID: 33551817
[No Abstract] [Full Text] [Related]
35. A systematic review of the antipsychotic properties of cannabidiol in humans.
Iseger TA; Bossong MG
Schizophr Res; 2015 Mar; 162(1-3):153-61. PubMed ID: 25667194
[TBL] [Abstract][Full Text] [Related]
36. Symptoms, adverse events, and outcomes in the use of medicinal cannabis in children and adolescents with autism spectrum disorder: a scoping review protocol.
Fletcher S; Pawliuk C; Ip A; Oberlander T; Siden H
JBI Evid Synth; 2021 May; 19(5):1251-1258. PubMed ID: 33165173
[TBL] [Abstract][Full Text] [Related]
37. A systematic review of the effect of cannabidiol on cognitive function: Relevance to schizophrenia.
Osborne AL; Solowij N; Weston-Green K
Neurosci Biobehav Rev; 2017 Jan; 72():310-324. PubMed ID: 27884751
[TBL] [Abstract][Full Text] [Related]
38. Therapeutic Use of Δ9-THC and Cannabidiol: Evaluation of a New Extraction Procedure for the Preparation of Cannabis-based Olive Oil.
Morini L; Porro G; Liso M; Groppi A
Curr Pharm Biotechnol; 2017; 18(10):828-833. PubMed ID: 29189144
[TBL] [Abstract][Full Text] [Related]
39. Dosage Related Efficacy and Tolerability of Cannabidiol in Children With Treatment-Resistant Epileptic Encephalopathy: Preliminary Results of the CARE-E Study.
Huntsman RJ; Tang-Wai R; Alcorn J; Vuong S; Acton B; Corley S; Laprairie R; Lyon AW; Meier S; Mousseau DD; Newmeyer D; Prosser-Loose E; Seifert B; Tellez-Zenteno J; Huh L; Leung E; Major P
Front Neurol; 2019; 10():716. PubMed ID: 31333569
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
